Cadian Capital Management, LP Sarepta Therapeutics, Inc. Transaction History

Cadian Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$82.38 - $131.64 $45.3 Million - $72.4 Million	-550,000 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$76.53 - $135.58 $53.8 Million - $95.2 Million	-702,500 Reduced 56.09%	550,000 $71 Million
Q3 2019 Nov 13, 2019	BUY	$72.81 - $156.91 $51.3 Million - $110 Million	704,000 Added 128.35%	1,252,500 $94.3 Million
Q2 2019 Aug 13, 2019	SELL	$112.21 - $151.95 $6.96 Million - $9.43 Million	-62,046 Reduced 10.16%	548,500 $83.3 Million
Q1 2019 May 14, 2019	BUY	$106.67 - $151.68 $35.1 Million - $49.9 Million	329,000 Added 116.85%	610,546 $72.8 Million
Q4 2018 Feb 13, 2019	SELL	$97.32 - $148.76 $10.3 Million - $15.8 Million	-106,054 Reduced 27.36%	281,546 $30.7 Million
Q3 2018 Nov 13, 2018	BUY	$115.31 - $161.51 $12.4 Million - $17.4 Million	107,600 Added 38.43%	387,600 $62.6 Million
Q2 2018 Aug 13, 2018	BUY	$71.74 - $153.69 $20.1 Million - $43 Million	280,000 New	280,000 $37 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Cadian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cadian Capital Management, LP with notifications on news.